NewsBenzingaXylem prevé BPA ajustado del cuarto trimestre de $1.39-$1.44 frente a una estimación de $1.63; prevé ventas de $2.300B frente a una estimación de $2.446B Xylem prevé BPA ajustado del cuarto trimestre de $1.39-$1.44 frente a una estimación de $1.63; prevé ventas de $2.300B frente a una estimación de $2.446B Benzinga 2026.10.27 10:57 (GMT+0) Open on Benzinga Other news Keybanc Reiterates Sector Weight on NVIDIAto Sector Weight Top 3 Tech Stocks That May Fall Off A Cliff This Month Truist Securities Maintains Hold on BILL Holdings, Raises Price Target to $66 Nvidia’s China Exit Could Trigger a Bull-Bear Showdown: 6 Leveraged ETFs to Watch Wednesday OTraces Selects Labcorp To Perform Reference Laboratory Testing For Florida Department Of Health–Funded Clinical Trial Evaluating OTraces Blood-Based Prostate Cancer Diagnostic Platform Quanterix Affirms FY2026 Sales Guidance of $142.000M-$146.000M vs $143.357M Est
OTraces Selects Labcorp To Perform Reference Laboratory Testing For Florida Department Of Health–Funded Clinical Trial Evaluating OTraces Blood-Based Prostate Cancer Diagnostic Platform